Backlog Visibility And Complex Bioconjugates Will Support A Stronger Long Term Outlook

Catalysts

About WuXi XDC Cayman

WuXi XDC Cayman is a contract research, development and manufacturing company focused on antibody drug conjugates and broader bioconjugate modalities.

What are the underlying business or industry changes driving this perspective?

• The growing use of antibody drug conjugates and newer bioconjugates such as AOCs and APCs is contributing to a larger addressable project funnel at WuXi XDC Cayman. This can support sustained revenue growth as more assets move from discovery to development and commercial manufacturing.
• The shift toward more complex formats such as dual payload and bispecific ADCs increases technical barriers and can favor WuXi XDC Cayman as clients look for integrated, high value services. This may support pricing power and net margins.
• The reported service backlog of around US$2.2b, including milestone potential, provides multi year visibility on contracted work. This can underpin future revenue and earnings as projects convert from backlog into recognized sales.
• The expansion of global capacity in China and Singapore, including PPQ and commercial ready facilities, positions WuXi XDC Cayman to capture end stage work as more programs seek BLAs. This can increase the mix of commercial revenue and support operating leverage.
• The build out of linker payload capabilities across highly potent linkers, peptides and oligos, together with more than 22,000 bioconjugate molecules made, ties WuXi XDC Cayman into the trend toward diversified payload platforms. This can broaden service scope per project and support gross margin through higher value contributions.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming WuXi XDC Cayman's revenue will grow by 30.9% annually over the next 3 years.
• Analysts assume that profit margins will increase from 22.4% today to 24.8% in 3 years time.
• Analysts expect earnings to reach CN¥3.9 billion (and earnings per share of CN¥2.85) by about September 2029, up from CN¥1.6 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as CN¥5.3 billion.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 33.0x on those 2029 earnings, down from 52.2x today. This future PE is greater than the current PE for the HK Life Sciences industry at 26.6x.
• Analysts expect the number of shares outstanding to grow by 0.5% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.06%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• WuXi XDC Cayman is adding significant capacity in China and Singapore while also integrating BioDlink. If industry demand for ADC and broader XDC services grows more slowly than current build outs, the company could face underutilized facilities, which would pressure revenue growth and compress net margins through higher fixed cost absorption.
• The ramp up of newer sites such as Singapore is expected to be slower than in China and currently carries loss making contributions from BioDlink. If commercialization and client audits take longer than management expects, the group could see weaker than anticipated operating leverage, which would weigh on earnings and limit further margin expansion.
• The business model depends heavily on a growing project funnel in complex ADC and XDC modalities and on a multi year service backlog of about US$2.2b. Any shift in client R&D priorities, slower advancement of PPQ projects into BLAs, or setbacks in key clinical assets could delay conversion of backlog into sales and affect both revenue and earnings visibility.
• Global competition in ADC and bioconjugate contract services from players such as Lonza and Samsung Bio is increasing. If these rivals secure a larger share of late stage and commercial projects or offer more attractive pricing or geographies, WuXi XDC Cayman could face pricing pressure and lower win rates, which would impact revenue growth and net margins.
• WuXi XDC Cayman is expanding into newer bioconjugate formats such as AOCs, APCs and degrader conjugates, and the technical and regulatory paths for these modalities are still evolving. If development challenges, safety concerns, or slower regulatory uptake limit their commercial adoption, the expected contribution from higher value projects could fall short and weigh on long term revenue, gross margin and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of HK$92.1 for WuXi XDC Cayman based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of HK$108.09, and the most bearish reporting a price target of just HK$71.09.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CN¥15.6 billion, earnings will come to CN¥3.9 billion, and it would be trading on a PE ratio of 33.0x, assuming you use a discount rate of 8.1%.
• Given the current share price of HK$74.85, the analyst price target of HK$92.1 is 18.7% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.